Shareholders OctoPlus appoint Susan Swarte to Executive Board and Nancy de Ruiter to Supervisory Board
(Thomson Reuters ONE) -
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery
company, announces today that its Annual General Meeting of Shareholders (the
"Meeting") has appointed Mrs. Susan Swarte to the Executive Board and has
appointed Mrs. Nancy de Ruiter to the Supervisory Board.
Mrs. Swarte has been appointed for a period of four years. Mrs. Swarte has over
16 years of experience in financial and strategic management and joined OctoPlus
on 1 August 2009 as Chief Financial Officer.
Mrs. De Ruiter was appointed for a period of four years. Mrs. De Ruiter has a
scientific background and has held several Supervisory Board positions. Mrs. De
Ruiter currently indirectly holds 3.0% of OctoPlus' outstanding shares through
ACEE B.V. but is independent within the meaning of the Dutch Corporate
Governance.
Next to the above appointments, Mr. Hans Stellingsma has been reappointed as
chairman of the Supervisory Board for a period of four years. Messrs. Philip
Smith and Paul Toon have resigned from the Supervisory Board today.
The shareholders also approved all other agenda items of today's Meeting.
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071 or
send an e-mail to Investor Relations at IR(at)octoplus.nl.
About OctoPlus
OctoPlus is a drug delivery company committed to the creation of improved
pharmaceutical products that are based on OctoPlus' proprietary drug delivery
technologies and have fewer side effects, improved patient convenience and a
better efficacy/safety balance than existing therapies. OctoPlus focuses on the
development of long-acting, controlled release versions of known protein
therapeutics, other drugs, and vaccines on behalf of its clients.
The clinically most advanced product incorporating our technology is Biolex
Therapeutics' lead product Locteron®, a controlled release formulation of
interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed
Locteron exclusively to Biolex in October 2008. Locteron is being manufactured
for Biolex by OctoPlus and is currently in Phase IIb clinical studies.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.
For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
[HUG#1415415]
Click here for the press release in PDF: http://hugin.info/137076/R/1415415/366631.pdf
Unternehmensinformation / Kurzprofil:
Datum: 12.05.2010 - 17:15 Uhr
Sprache: Deutsch
News-ID 20829
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 228 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Shareholders OctoPlus appoint Susan Swarte to Executive Board and Nancy de Ruiter to Supervisory Board"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
